José Ángel Arranz

Publications (2)10.56 Total impact

• Article: Recommendations for the optimal management of early and advanced urothelial carcinoma.

  Daniel Castellano, Joan Carles, Emilio Esteban, José Manuel Trigo, Miguel Ángel Climent, José Pablo Maroto, Xavier García del Muro, Albert Font, Luis Paz-Ares, José Ángel Arranz, Joaquim Bellmunt
  [show abstract] [hide abstract]
  ABSTRACT: The field of urothelial carcinoma has shown considerable advances in terms of diagnosis, staging, and treatment. The increasing knowledge of molecular pathways and genes involved in the occurrence of this tumor has encouraged the search for new, more effective and less toxic therapies, and has prompted the design and development of clinical trials. However, the speed at which results are published makes it difficult for clinicians to cover the vast amount of information available. Moreover, in clinical practice some gaps remain concerning treatment options for patients who have progressed after first-line cisplatin-based combinations, who cannot tolerate cisplatin-based chemotherapy, or who have received platinum-based neoadjuvant or adjuvant therapy, and thus cannot be offered this option on disease progression. The purpose of this review is to issue a series of recommendations on the optimal management of early and advanced urothelial carcinoma based on current evidence and the available updated guidelines.
  Cancer treatment reviews 11/2011; 38(5):431-41. · 5.30 Impact Factor
• Article: Sorafenib in renal cell carcinoma.

  José Ángel Arranz, Miguel Ángel Climent, José Luis González-Larriba, Luis León, José Pablo Maroto
  [show abstract] [hide abstract]
  ABSTRACT: Metastatic renal cell carcinoma is resistant to conventional treatment with chemotherapy. Recently the use of molecular-targeted therapies with multikinase inhibitors has been recommended as first-choice therapy because they inhibit cell proliferation and tumour angiogenesis. Sorafenib is a well tolerated tyrosine kinase inhibitor that initially demonstrated efficacy in the treatment of patients with metastatic RCC who progressed after immunotherapy. Expanded-access studies in Europe and North America showed the safety and efficacy of sorafenib in special populations such as elderly, renal failure and cerebral metastases, as well as patients with no prior therapy. No cross-resistance has been suggested in non-randomized trials when used in second line treatment after other targeted therapies. Ongoing clinical trials will better define the role of sorafenib in first and second line either as monotherapy or in combination, as well as the best strategies for the sequential use of this drug.
  Critical reviews in oncology/hematology 03/2011; 80(2):314-22. · 5.27 Impact Factor